307 related articles for article (PubMed ID: 17438265)
21. The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2.
Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
Biochem J; 2004 Aug; 381(Pt 3):685-91. PubMed ID: 15154850
[TBL] [Abstract][Full Text] [Related]
22. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
[TBL] [Abstract][Full Text] [Related]
23. Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function.
Thomas A; White E
Genes Dev; 1998 Jul; 12(13):1975-85. PubMed ID: 9649502
[TBL] [Abstract][Full Text] [Related]
24. Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity.
Sang N; Avantaggiati ML; Giordano A
J Cell Biochem; 1997 Sep; 66(3):277-85. PubMed ID: 9257185
[TBL] [Abstract][Full Text] [Related]
25. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression.
Wadgaonkar R; Collins T
J Biol Chem; 1999 May; 274(20):13760-7. PubMed ID: 10318779
[TBL] [Abstract][Full Text] [Related]
26. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain.
Wells M; Tidow H; Rutherford TJ; Markwick P; Jensen MR; Mylonas E; Svergun DI; Blackledge M; Fersht AR
Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5762-7. PubMed ID: 18391200
[TBL] [Abstract][Full Text] [Related]
27. Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein.
Ferreon JC; Martinez-Yamout MA; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13260-5. PubMed ID: 19651603
[TBL] [Abstract][Full Text] [Related]
28. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
29. Structure of the Taz2 domain of p300: insights into ligand binding.
Miller M; Dauter Z; Cherry S; Tropea JE; Wlodawer A
Acta Crystallogr D Biol Crystallogr; 2009 Dec; 65(Pt 12):1301-8. PubMed ID: 19966416
[TBL] [Abstract][Full Text] [Related]
30. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
31. Binding Kinetics of the Intrinsically Disordered p53 Family Transactivation Domains and MDM2.
Åberg E; Karlsson OA; Andersson E; Jemth P
J Phys Chem B; 2018 Jul; 122(27):6899-6905. PubMed ID: 29878773
[TBL] [Abstract][Full Text] [Related]
32. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.
Dornan D; Shimizu H; Burch L; Smith AJ; Hupp TR
Mol Cell Biol; 2003 Dec; 23(23):8846-61. PubMed ID: 14612423
[TBL] [Abstract][Full Text] [Related]
33. The C terminus of p53 binds the N-terminal domain of MDM2.
Poyurovsky MV; Katz C; Laptenko O; Beckerman R; Lokshin M; Ahn J; Byeon IJ; Gabizon R; Mattia M; Zupnick A; Brown LM; Friedler A; Prives C
Nat Struct Mol Biol; 2010 Aug; 17(8):982-9. PubMed ID: 20639885
[TBL] [Abstract][Full Text] [Related]
34. Structural details on mdm2-p53 interaction.
Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
[TBL] [Abstract][Full Text] [Related]
35. DNA-dependent acetylation of p53 by the transcription coactivator p300.
Dornan D; Shimizu H; Perkins ND; Hupp TR
J Biol Chem; 2003 Apr; 278(15):13431-41. PubMed ID: 12499368
[TBL] [Abstract][Full Text] [Related]
36. Differences in the transactivation domains of p53 family members: a computational study.
Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
[TBL] [Abstract][Full Text] [Related]
37. p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300.
Livengood JA; Scoggin KE; Van Orden K; McBryant SJ; Edayathumangalam RS; Laybourn PJ; Nyborg JK
J Biol Chem; 2002 Mar; 277(11):9054-61. PubMed ID: 11782467
[TBL] [Abstract][Full Text] [Related]
38. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
39. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.
Ha JH; Shin JS; Yoon MK; Lee MS; He F; Bae KH; Yoon HS; Lee CK; Park SG; Muto Y; Chi SW
J Biol Chem; 2013 Mar; 288(10):7387-98. PubMed ID: 23316052
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
Feng H; Jenkins LM; Durell SR; Hayashi R; Mazur SJ; Cherry S; Tropea JE; Miller M; Wlodawer A; Appella E; Bai Y
Structure; 2009 Feb; 17(2):202-10. PubMed ID: 19217391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
